Managing childhood atopic dermatitis

Advances in Therapy

Volumn 20, Issue 3, 2003, Pages 129-137

  Leung, Alexander K C ^a,c   Barber, Kirk A ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE   (Canada)

Author keywords

Atopic dermatitis; Children; Immunomodulator; Pimecrolimus; Tacrolimus

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CLOXACILLIN; COAL TAR; CORTICOSTEROID; CYCLOSPORIN A; CYPROHEPTADINE; CYTOKINE; DIPHENHYDRAMINE; FUSIDIC ACID; HYDROCORTISONE ACETATE; HYDROXYZINE; IMMUNOMODULATING AGENT; LORATADINE; MACROLIDE; PIMECROLIMUS; PSEUDOMONIC ACID; TACROLIMUS; TERFENADINE;

ACNE; ADRENAL SUPPRESSION; ATOPIC DERMATITIS; BACTERIAL INFECTION; CATARACT; CHILD; CLINICAL FEATURE; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; CUSHING SYNDROME; CYTOKINE RELEASE; DEPIGMENTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ERYTHEMA; FOLLICULITIS; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYPERTENSION; IMPETIGO; IRRITANT DERMATITIS; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; PERIORAL DERMATITIS; PHOTOSENSITIVITY DISORDER; PHOTOTHERAPY; PHOTOTOXICITY; PRURITUS; QUALITY OF LIFE; REVIEW; ROSACEA; SCHOOL CHILD; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN CARE; SKIN INFLAMMATION; SKIN PIGMENTATION; STRIA; TACHYPHYLAXIS; TELANGIECTASIA; ULTRAVIOLET RADIATION;

EID: 0042527659     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850199     Document Type: Review

References (58)

1. Leung AK, Martin S. Drug therapy for some common pediatric skin eruptions. Drug Protocol. 1987;2:9-20.
2. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:491-504.
3. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adults and pediatric patients with atopic dermatitis. J Am Acad Dermatol. 2001; 44:S65-S72.
4. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002;41:151-158.
5. DiCarlo JB, McCall CO. Pharmacologic alternatives for severe atopic dermatitis. Int J Dermatol. 2001;40:82-88.
6. Schultz Larsen E. Atopic dermatitis: a genetic epidemiologic study in a population based twin sample. J Am Acad Dermatol. 1993;28:719-723.
7. Knoell KA, Greer KE. Atopic dermatitis. Pediatr Rev. 1999;20:46-51.
8. Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party's diagnostic criteria for atopic dermatitis, III: independent hospital validation. Br J Dermatol. 1994;131:406-416.
9. Fleischer AB Jr. Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroid therapy. J Allergy Clin Immunol. 1999;104:S126-S130.
10. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721.
11. Kristal L, Klein PA. Atopic dermatitis in infants and children. Pediatr Clin North Am. 2000;47:877-895.
12. Eigenmann PA. Clinical features and diagnostic criteria of atopic dermatitis in relation to age. Pediatr Allergy Immunol. 2001;12(suppl 14):69-74.
13. Leung DY, Tharp M, Boguniewicz M. Atopic dermatitis (atopic eczema). In: Freedberg IM, Eisen AZ, Wolft K, et al, eds. Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill; 1999:1464-1480.
14. Whalley D, Huels J, McKenna SP. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics. 2002;110:1133-1136.
15. Hogan PA. Atopic dermatitis: what to do when the itch becomes too much. Med J Aust. 1996; 164:736-741.
16. Rothe MJ, Grant-Kels JM. Atopic dermatitis: an update. J Am Acad Dermatol. 1996;35:1-13.
17. Gontzes P, Bahna SL. Food allergy for the primary care physician. Prim Care. 1987;14:547-558.
18. Sampson HA. The immunopathogenic role of food hypersensitivity in atopic dermatitis. Acta Derm Venereol. 1992;176:S34-S37.
19. Leung AK. Food allergy: a clinical approach. Adv Pediatr. 1998;45:145-177.
20. Kemp AS. Food allergy in children. Aust Fam Physician. 1993;22:1959-1963.
21. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr. 2000;39:1-14.
22. Hanifin JM. Atopic dermatitis in infants and children. Pediatr Clin North Am. 1991;38:763-789.
23. Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr. 1985;107:669-675.
24. Lewis-Jones S. Atopic dermatitis in childhood. Hosp Med. 2001;62:136-143.
25. Vandenplas Y. The use of hydrolysates in allergy prevention programmes. Eur J Clin Nutr. 1995; 49:S84-S91.
26. Leung AK, Bowen TJ. Seasonal allergic rhinitis and food allergy. In: Bergman AB, ed. Twenty Common Problems in Pediatrics. New York: McGraw-Hill; 2001:219-233.
27. Correale C, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician. 1999;60:1191-1198.
28. Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14:321-324.
29. Denman ST. A review of pruritus. J Am Acad Dermatol. 1986;14:375-392.
30. Leung AK, Wong BE, Chan PY, et al. Pruritus in children. J R Soc Health. 1998;118:280-286.
31. Pustisek N, Lipozencic J, Ljubojevics S. Tacrolimus ointment: a new therapy for atopic dermatitis - review of the literature. Acta Dermatovenerol Croat. 2002;10:25-32.
32. Woodmansee D, Christiansen S. Atopic dermatitis. Pediatr Ann. 1998;27:710-716.
33. Ruiz-Maldonado R, Zapata G, Tamayo L, et al. Cushing's syndrome after topical application of corticosteroids. Am J Dis Child. 1982;136:274-275.
34. Stoppoloni G, Prisco F, Santinelli R, et al. Potential hazards of topical steroid therapy. Am J Dis Child. 1983;137:1130-1131.
35. Allen BR. Tacrolimus ointment: its place in the therapy of atopic dermatitis. J Allergy Clin Immunol. 2002;109:401-403.
36. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr. 2002;14:414-418.
37. Kim HJ, Honig PJ. Atopic dermatitis. Curr Opin Pediatr. 1998;10:387-392.
38. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998;102:637-644.
39. Hanifin J, Ling M, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part I: efficacy. J Am Acad Dermatol. 2001;44(suppl):S28-S38.
40. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44:S58-S64.
41. Paller A, Eichenfield L, Leung D, et al. A 12 week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44:S47-S57.
42. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816-821.
43. Soter N, Fleischer AB Jr, Webster G, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients, part II: safety. J Am Acad Dermatol. 2001;44(suppl):S39-S46.
44. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allegy Clin Immunol. 2002;109:547-555.
45. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539-546.
46. Bekersky I, Fitzsimmons W, Tanase A, et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol. 2001;44:S17-S27.
47. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111:396-398.
48. Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol. 2002; 47:562-570.
49. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000;136:999-1006.
50. Paller A, Hanifin J, Eichenfield L, et al. Long-term safety of topically applied tacrolimus ointment in pediatric patients 2-15 years of age with atopic dermatitis. J Eur Acad Dermatol Venereol. 2002; 16(suppl 1):136. Abstract.
51. Luger T, van Leent EJ, Graeber M, et al. SDZ AZM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144:788-794.
52. Van Leent FJ, Gräber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134:805-809.
53. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs. 2002;62:817-840.
54. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
55. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001;144:781-787.
56. Reitamo S, Remitz A, Kyllonen H, et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3:381-388.
57. Naylor MF, Elmets CA, Satoi MS, et al. Treatment with tacrolimus ointment is not associated with an increase in non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2002;16(suppl 1):138. Abstract.
58. Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol. 2001;2:389-406.